Dompé Farmaceutici Explained

Dompé Farmaceutici is a privately held pharmaceutical company based in Milan. Founded as a compounding pharmacy in 1890 by Piedmontese Onorato Dompé, the company has grown to a global pharmaceutical company with around 900 employees.[1] His son, Sergio Dompe is the current CEO.

In 2012, Dompé acquired the eye health-focused Italian pharmaceutical company Anabasis Srl;[2] they went on to develop the Anabasis product cenegermin, an eye drop containing recombinant human nerve growth factor, as a treatment for neurotrophic keratitis.[3] Cenegermin was approved by the FDA in August 2018 as the first available treatment for neurotrophic keratitis, and received orphan drug designation. Cenegermin is marketed under the name Oxervate.[4] In the same year, the company announced plans to list shares as part of its move to focus on biotechnology and the treatment of specific diseases.

Notes and References

  1. News: Italy's Dompe Farmaceutici mulls listing as part of shift to biotech . Reuters . 25 October 2018 . 20 February 2023.
  2. Web site: Dompé to acquire 100% of Anabasis, an Italian biopharmaceutical ophthalmology company . 20 February 2023 . 28 February 2012 . Business Wire.
  3. Web site: Cenegermin - Dompe Farmaceutici . 20 February 2023 . Adis Insight . 11 February 2022.
  4. Web site: FDA approves first drug for neurotrophic keratitis, a rare eye disease . 20 February 2023 . FDA.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Dompé Farmaceutici".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.